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Dear Editor, 
 
Pakistan with its teeming population and 
economical and security setbacks cannot turn 
away from the escalating health issues which are 
important indicators for the development of a 
nation. Clinical research has shown tremendous 
growth in the past few years. The clinical trial, 
which is the process of evaluation of drug safety 
and its potential benefits
[1]
 is increasingly a point 
of interest by both multinational and national 
pharmaceutical companies. This business has 
progressed significantly in the past few years.
[2]
 
The drug companies are making due efforts in 
order to gain maximum benefits from this 
progressing field in terms of business.
[3]
 This has 
resulted in some negativism. The three Cs of 
Convince, Confuse and Corrupt of Chandra 
Gulhati very truly project the current situation.  I 
will go through some points which I observe, 
regarding the clinical trials in our country. 
 
The patient enrollment was the first to seek 
attention, as the pharmaceutical companies has 
to enroll patients for their clinical trials; they visit 
the areas which have low literacy rate, low 
average household income and less knowledge 
about the rights of the study participant. The 
reason for this is because the companies are 
striving for meeting their timelines, smooth patient 
enrollments and low dropouts. The low literacy 
rate makes the individuals unable to understand 
the rationale of the trial and also if it does, they 
can easily be confused. The consent forms which 
if used are not explaining the core essence of the 
trials, and are not translated. The forms are 
grossly inadequate. There is a significant media 
and literature scarcity for the people to know 
about their rights. Ideally, the knowledge of the 
rights of an individual when registering into a 
clinical trial must trickle at all levels of our society 
if one wants to help humanity.  Clinical trial is an 
area which still needs powerful media campaign 
which should focus on both the pros and cons. 
The individual has to be given the advantage of 
making decision by himself/herselfand not 
through the research assistants who lure them in 
order to gain financial benefits. 
 
Also, the appointment of the research assistants 
which are mostly medical students or the young 
medical graduates is a major issue. They are not 
aware of the significance of the trials nor are they 
trained in terms of the International Conference 
on Harmonization and Good Clinical Practice 
Guidelines (ICH GCP guidelines). This accounts 
for one of the reasons of high dropout rates 
compared to the developed countries. The 
assistants must know their rights and more 
importantly the rights of the participants. The 
pharmaceutical companies must set a point of 
training all the individuals whom they hire as 
research assistants. In most cases, the research 
assistants are working as coordinators, clinical 
research associate (CRA) and monitors, which is 
one of the reasons of the mismanagement of the 
data mostly seen in studies. The saturation in the 
USA has resulted in the shifting of these trials to 
South-East Asia mainly because of the good 
enrollment rates due to low literacy, poverty and 
large population. The increasing national drug 
industry growth compare to the multinationals
[4]
 
has not been good in terms of protecting the 
ethical rights of the individual because they are 
more concern for meeting their timelines and 
patient enrollments not paying due attention to 
the ethical chapter which is of pivotal importance. 
By formulating necessary guidelines, we can 
Waheed and Siddiqui: Clinical trials and research ethics in Pakistan 
Int J Med Biomed Res 2013;2(2):161-162 
 
 
162 
 
  
optimistically produce refined research assistants 
which will be of benefit for clinical trials and 
medical research.  
 
Furthermore, there should be proper patient 
education before the enrollment process. They 
should be given time and materials which should 
include necessary information regarding the 
efficacy, side effects and adverse effects of the 
drug simply written in both English and Urdu. The 
drop out from the study is mainly due to lack of 
proper description of the study to participants. 
Soon, individuals will lose faith in the doctors and 
there will be no enrollments if this issue is not 
addressed. The need for the availability of 
platform for improving legal protection in 
particular, providing protection to test data is 
paramount. This is of the reason because 
companies invest in countries where there are 
laws for the protection of the study participants. A 
very relevant example is of Jordan which has 
shown increase in both research and 
development and also the exponential growth of 
the pharmaceutical industries due to the 
implementation of these reforms.
[2]
 Although there 
are number of trials going on in the country, we 
find very few full filling the standards. 
 
Ethics is not a new chapter in our part of the 
world. For the past few years, it has emerged as 
an essential constituent for every institution 
carrying out research.
[5]
 Ethical approval is now 
an integral essence to have international 
collaborations and for obtaining funding. 
However, there are some impurities mixing in it as 
time passes. Although it has some very significant 
positivism after its implementation the need to 
safeguard it and to make a check on it is also 
important. To begin with, the drug companies are 
approaching different institutions for an easy 
ethical approval to get their trial started and to 
add on to it, there are also some incentives 
getting into play in this drama. This has shown 
some serious upsets in terms of quality. The 
formation of Ethical Review Boards is a very bold 
and a much needed step taken from our part of 
the world. Educating the masses, including the 
medical professionals must also be considered. 
For a start of a successful program, it must have 
its acceptance from the grass root level and the 
young graduates and medical students can 
provide us the necessary spice needed. Ethics 
must not be limited to obtaining ERC approval. It 
must diffuse into all aspects of the medical 
profession. Few institutions have their 
independent ethics setup which is working 
effectively but we find chaos at the government 
hospitals. 
  
Despite these, I appreciate the efforts being taken 
by people at different levels for the progress of 
clinical trial and ethics, but there is much more 
which can be done and we are very optimistic that 
in the near future, this will improve.  
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